Zivo Bioscience, Inc. Common Stock
ZIVO
ZIVO was delisted on the 24th of November, 2023.
2 hedge funds and large institutions have $30.1K invested in Zivo Bioscience, Inc. Common Stock in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
30% less capital invested
Capital invested by funds: $43.2K → $30.1K (-$13.1K)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KBFS
Kohmann Bosshard Financial Services
Fairlawn,
Ohio
|
-$4.35K |
ZIVO Hedge Fund Activity: Q1 2026 in Review
2 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Zivo Bioscience, Inc. Common Stock (ZIVO) for Q1 2026, worth a combined $30.1K — down 30% from $43.2K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ZIVO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Kohmann Bosshard Financial Services, exiting entirely with an estimated $4.35K sold.
- 2 institutional investors held Zivo Bioscience, Inc. Common Stock (ZIVO) as of Q1 2026, down from 3 in Q4 2025.
- Funds reported $30.1K of Zivo Bioscience, Inc. Common Stock stock for Q1 2026, down 30% quarter-over-quarter.
- 0 funds opened new Zivo Bioscience, Inc. Common Stock positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Zivo Bioscience, Inc. Common Stock seller in Q1 2026 was Kohmann Bosshard Financial Services, an estimated $4.35K sold.
Based on aggregated 13F filings for Q1 2026.